LINC00891 Promotes Tumorigenesis and Metastasis of Thyroid Cancer by Regulating SMAD2/3 EZH2.
1/5 보강
[BACKGROUND] Thyroid cancer (TC), the most common endocrine malignant tumor, is increasingly causing a huge threat to our health nowadays.
APA
Si Y, Wen J, et al. (2024). LINC00891 Promotes Tumorigenesis and Metastasis of Thyroid Cancer by Regulating SMAD2/3 EZH2.. Current medicinal chemistry, 31(24), 3818-3833. https://doi.org/10.2174/0929867330666230522115945
MLA
Si Y, et al.. "LINC00891 Promotes Tumorigenesis and Metastasis of Thyroid Cancer by Regulating SMAD2/3 EZH2.." Current medicinal chemistry, vol. 31, no. 24, 2024, pp. 3818-3833.
PMID
37221682
Abstract
[BACKGROUND] Thyroid cancer (TC), the most common endocrine malignant tumor, is increasingly causing a huge threat to our health nowadays.
[METHODS] To explore the tumorigenesis mechanism of thyroid cancer, we identified that long intergenic non-coding RNA-00891 (LINC00891) was upregulated in TC using the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and local databases. LINC00891 expression was correlated with histological type and lymph node metastasis (LNM). The high expression of LINC00891 could serve as a diagnostic marker for TC and its LNM. experiments demonstrated that LINC00891 knockdown could inhibit cell proliferation, migration, invasion and prompt apoptosis and G1 arrest of TC cells. We also investigated the related mechanisms of LINC00891 promoting TC progression using RNA sequencing, Gene Set Enrichment Analysis, and Western blotting.
[RESULTS] Our experiments demonstrated that LINC00891 promoted TC progression via the EZH2-SMAD2/3 signaling axis. In addition, overexpression of EZH2 could reverse the suppressive epithelial-to-mesenchymal transition (EMT) caused by LINC00891 knockdown.
[CONCLUSION] In conclusion, the LINC00891/EZH2/SMAD2/3 regulatory axis participated in tumorigenesis and metastasis of thyroid cancer, which may provide a novel target for treatment.
[METHODS] To explore the tumorigenesis mechanism of thyroid cancer, we identified that long intergenic non-coding RNA-00891 (LINC00891) was upregulated in TC using the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and local databases. LINC00891 expression was correlated with histological type and lymph node metastasis (LNM). The high expression of LINC00891 could serve as a diagnostic marker for TC and its LNM. experiments demonstrated that LINC00891 knockdown could inhibit cell proliferation, migration, invasion and prompt apoptosis and G1 arrest of TC cells. We also investigated the related mechanisms of LINC00891 promoting TC progression using RNA sequencing, Gene Set Enrichment Analysis, and Western blotting.
[RESULTS] Our experiments demonstrated that LINC00891 promoted TC progression via the EZH2-SMAD2/3 signaling axis. In addition, overexpression of EZH2 could reverse the suppressive epithelial-to-mesenchymal transition (EMT) caused by LINC00891 knockdown.
[CONCLUSION] In conclusion, the LINC00891/EZH2/SMAD2/3 regulatory axis participated in tumorigenesis and metastasis of thyroid cancer, which may provide a novel target for treatment.
🏷️ 키워드 / MeSH
- Humans
- Thyroid Neoplasms
- Enhancer of Zeste Homolog 2 Protein
- RNA
- Long Noncoding
- Smad3 Protein
- Smad2 Protein
- Cell Proliferation
- Cell Movement
- Cell Line
- Tumor
- Carcinogenesis
- Epithelial-Mesenchymal Transition
- Apoptosis
- EZH2
- LINC00891
- SMAD2/3
- epithelial-to-mesenchymal transition
- gene expression omnibus.
- thyroid cancer
같은 제1저자의 인용 많은 논문 (3)
- Fully Exposed Platinum-Palladium Heteronuclear Cluster for Enhanced Multi-Step Hydrogenation of Dinitroaromatics.
- binds to to activate the cyclic guanosine monophosphate-protein kinase G pathway, promoting gastric cancer progression.
- [Preliminary efficacy and safety of pembrolizumab combined with chemotherapy as neoadjuvant therapy for advanced temporal bone squamous cell carcinoma].